10.1007/s10637-019-00755-x - Eribulin, trastuzumab, and pertuzumab...

This document has been corrected

Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial

10.1007/s10637-019-00755-x

Published Online: 2019-03-08

Journal: Investigational New Drugs•Publisher: Springer Science and Business Media LLC

Authors: •Hirofumi Yamada•Jun Ninomiya•Katsuhiko Okubo•Kei Kimizuka•Kenichi Inoue•Takashi Nakakuma•Tohru Higuchi•Tsuyoshi Saito

This document has been corrected

Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial

10.1007/s10637-019-00755-x

Published Online: 2019-03-08

Journal: Investigational New Drugs

Authors: Hirofumi Yamada•Jun Ninomiya•Katsuhiko Okubo•Kei Kimizuka•Kenichi Inoue•Takashi Nakakuma•Tohru Higuchi•Tsuyoshi Saito

NOW

2019-04-25•Correction

Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial

10.1007/s10637-019-00773-9

* information provided by CrossRef

2019-04-25•Correction

10.1007/s10637-019-00773-9

* information provided by CrossRef

2019-03-08•Published

2019-04-25•Correction

10.1007/s10637-019-00773-9

* information provided by CrossRef

This document has been corrected

Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial

10.1007/s10637-019-00755-x

Published Online: 2019-03-08

Journal: Investigational New Drugs•Publisher: Springer Science and Business Media LLC

Authors: •Hirofumi Yamada•Jun Ninomiya•Katsuhiko Okubo•Kei Kimizuka•Kenichi Inoue•Takashi Nakakuma•Tohru Higuchi•Tsuyoshi Saito